FDA grants full approval to first drug for rare kidney disease
FDA 全面批准首款用於治療罕見腎臟疾病的藥物
Food and Drug Administration (FDA) reached a historic milestone by granting full approval to Filspari (sparsentan).
這款藥物是史上首個專門針對局部節段性腎絲球硬化症（FSGS）核准的治療藥物，這是一種罕見且嚴重的腎臟疾病。
This medication is the first-ever treatment specifically approved for focal segmental glomerulosclerosis (FSGS), a rare and serious kidney disease.
FSGS會導致腎臟的過濾單元出現疤痕，經常引發器官完全衰竭。
FSGS causes scarring in the kidney’s filtering units, often leading to total organ failure.
多年來，病患只能依賴類固醇等適應症外的治療，這些藥物往往伴隨著嚴重的副作用。
For years, patients relied on off-label treatments like steroids, which frequently came with severe side effects.
Filspari是一種每日服用一次的口服藥物，透過標靶導致疤痕和蛋白尿的發炎路徑來發揮作用。
Filspari, an oral, once-daily drug, works by targeting the inflammatory pathways that cause scarring and protein leakage.
在大型第三期DUPLEX研究的支持下，該藥物顯示出與傳統降血壓藥物相比，能顯著降低蛋白尿。
While it carries a warning for liver toxicity, its approval offers new hope to over 30,000 patients in the United States who previously lacked a dedicated therapy.
透過聚焦於降低蛋白尿，Filspari符合現代臨床準則，這標誌著醫學界在減緩慢性腎臟病惡化並改善病患長期預後方面的重大成功。
By focusing on proteinuria reduction, Filspari aligns with modern clinical guidelines, marking a major success in the medical community’s effort to slow the progression of chronic kidney conditions and improve long-term outcomes for those living with this challenging disease.
